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BACKGROUND: Synchronous metastases of colorectal cancer (CRC) are considered to be of worse prognostic value compared with
metachronous metastases, but only few and conflicting data have been reported on this issue.
METHODS: We retrospectively investigated patient demographics, primary tumour characteristics and overall survival (OS) in 550
advanced CRC patients with metachronous vs synchronous metastases, who participated in the phase III CAIRO study. For this
purpose only patients with a prior resection of the primary tumour were considered.
RESULTS: The clinical and pathological characteristics associated with poor prognosis that we observed more often in patients with
synchronous metastases (n¼ 280) concerned an abnormal serum lactate dehydrogenase (LDH) concentration (P¼ 0.01), a worse
WHO performance status (P¼ 0.02), primary tumour localisation in the colon (P¼ 0.002) and a higher T stage (P¼ 0.0006). No
significant difference in median OS was observed between patients with synchronous metastases and metachronous metastases
(17.6 vs 18.5 months, respectively, P¼ 0.24).
CONCLUSION: Despite unfavourable clinicopathological features in patients with synchronous metastases with a resected primary
tumour compared to patients with metachronous metastases, no difference in the median OS was observed. Possible explanations
include a (partial) chemoresistance in patients with metachronous disease because of previous adjuvant treatment, whereas
differences between the two groups in screening procedures resulting in a lead time bias to diagnosis or in prognostic molecular
markers remain speculative.
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Approximately 20% of colorectal cancer (CRC) patients present
with synchronous distant metastases at the initial diagnosis, and
about 50% of the patients without metastases at presentation
develop distant metastases within 3 years of diagnosis (McArdle,
2000). For patients with unresectable metastatic CRC there are no
curative options, but a significant benefit in median overall
survival can be achieved with palliative systemic treatment
(Golfinopoulos et al, 2007). This treatment consists of cytotoxic
chemotherapy (fluoropyrimidines, oxaliplatin, irinotecan) and
targeted therapy (VEGF and EGFR antibodies).
Only few data have been reported on the prognostic role of
synchronous and metachronous metastases in patients with
advanced CRC treated with chemotherapy, and the results are
conflicting. Moreover, there is no consensus about the definition of
synchronous and metachronous disease. Synchronous metastases
were defined as metastases detected by pre-operative screening or
during resection of the primary tumour (Manfredi et al, 2006;
Miller et al, 2007; van der Pool et al, 2009), and occurring within 3
(Ng et al, 2009), 6 (Wang et al, 2007; Pantaleo et al, 2008) or
12 months (Tsai et al, 2007; Bockhorn et al, 2008) of the initial
diagnosis of CRC. It is not clear whether patients with synchronous
vsmetachronous metastases may represent two different categories
of CRC. Only in some surgical intervention trials the clinicopatho-
logical features have been compared between patients with
metachronous and synchronous metastases (Tsai et al, 2007;
Wang et al, 2007; Ng et al, 2009). However, these studies involved
small numbers of patients, and only limited clinical and
pathological features were evaluated.
In a review of 143 phase II and III studies with 21 214 metastatic
colorectal cancer patients, metachronous vs synchronous metas-
tases were reported as baseline characteristics in only 18 studies
(Sorbye et al, 2007). Consequently, few data are available on the
prognostic value of this parameter with conflicting results (Nordic
Gastrointestinal Tumor Adjuvant Therapy Group, 1992; Graf et al,
1994; Freyer et al, 2000; Saltz et al, 2000; Tournigand et al, 2004;
Colucci et al, 2005).
To our knowledge, this is the first large retrospective analysis on
the clinical and pathological characteristics of advanced CRC
patients with metachronous vs synchronous metastases, and their
correlation with outcome. Data were obtained from the phase III
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CAIRO study of the Dutch Colorectal Cancer Group (DCCG)
(Koopman et al, 2007a).
MATERIALS AND METHODS
Patients
Data were used from the phase III CAIRO study of the DCCG
(Koopman et al, 2006, 2007a). In this study patients were
randomised between sequential and combination treatment with
capecitabine, irinotecan and oxaliplatin. Stratification parameters
included WHO performance status, serum lactate dehydrogenase
(LDH), prior adjuvant therapy, predominant localisation of
metastases and participation institution. Assessment of tumour
response was scheduled every three cycles (9 weeks) according to
RECIST criteria (Therasse et al, 2000). Follow-up after completion
of treatment was performed every 3 months until death. The
primary endpoint was overall survival.
Patients were divided into synchronous and metachronous
disease, with synchronous disease defined as distant metastases
occurring within, and metachronous disease beyond 6 months of
the primary diagnosis of CRC. For two reasons only patients in
whom a resection of the primary tumour had been performed were
included in the analysis. First, tissue of the primary tumour was
required for histopathological review. Second, the arguments for
non-resection may greatly vary from patients with an asympto-
matic primary and excellent performance status to patients with a
symptomatic primary with extensive metastases and poor
performance status in whom a delay in systemic treatment is not
warranted. These arguments are often not recorded in the
patients’ files.
Pathological procedures and parameters
Standardised pathology examination was performed in the
pathology laboratories of the referring hospitals. The maximum
diameter was noted with an invasion depth described in terms of
the T classification and lymph node stage in terms of the N
classification (Sobin and Fleming, 1997). All reports of these
examinations with haematoxylin and eosin-stained coupes of the
primary tumours were collected. Histopathological review was
carried out by two independent observers. If the scoring was not
unambiguous, the two observers discussed until agreement was
reached. Classification of the tumours was performed using the
World Health Organization guidelines (Hamilton and Aaltonen,
2000). A tumour was considered to be of the mucinous type when
at least 50% of the tumour was mucinous. The tumours were
graded according to the grade of differentiation into well,
moderate and poor adenocarcinomas on the basis of the part of
poorest differentiation in the tumour. Growth pattern, the
presence of inflammatory reaction and fibroblastic reaction were
assessed according to Jass et al (1987). The mismatch repair
system status was determined by immunohistochemistry and
microsatellite instability (MSI) analysis (Koopman et al, 2009).
Statistical analysis
The comparison of patient and primary tumour characteristics
between patients with synchronous and metachronous metastases
was done using Wilcoxon’s rank sum test or w2-test where
appropriate. The progression-free survival (PFS) for first line
treatment was calculated from the date of randomisation to
the first observation of disease progression or death from any
cause. Overall survival and PFS curves were estimated using the
Kaplan–Meier method and compared with the log-rank test.
Multivariate analysis of survival was performed by means of a Cox
proportional hazard model. Patients were considered evaluable for
response if they had completed at least three cycles of
chemotherapy. Overall response was defined as partial response
or complete response. Disease control was defined by stable
disease with a duration of more than 4 months or partial response
or complete response (Therasse et al, 2000). Differences in
response and disease control rates were analysed by a
w2 (univariate) model. All tests were two-sided and P-values of
less than 0.05 were considered statistically significant. The analyses
were performed using SAS 8.2 software.
RESULTS
Patient characteristics
In 550 of 803 eligible patients in the CAIRO study, a resection of
the primary tumour was performed and material for histological
review of the primary tumour was available, and these 550 patients
were included in this analysis. Compared to the metachronous
group (n¼ 270), patients with synchronous metastases (n¼ 280)
were younger (Po0.0001), had more often an abnormal serum
LDH at randomisation (P¼ 0.01) and more often the liver as
predominant site of metastases (Po0.0001). Primary tumour
localisation in the colon (P¼ 0.002), a worse WHO performance
status at randomisation (P¼ 0.02) and no previous adjuvant
chemotherapy (Po0.0001) were more frequently observed in
patients with synchronous metastases (Table 1).
Primary tumour characteristics
Tumours of patients with synchronous metastases had larger
diameters (P¼ 0.007), a higher T (P¼ 0.0006) and N stage
(Po0.0001), absent or little lymphoid reaction (P¼ 0.04) and
more frequently a diffuse infiltration pattern (P¼ 0.02) than
patients with metachronous disease. There were no significant
differences between the synchronous and metachronous group in
terms of classification, differentiation grade, MSI status, and
fibroblastic reaction surrounding the tumour (Table 2).
Correlation of clinical and pathological characteristics
with outcome
The effect of clinical and pathological characteristics on median
overall survival (OS) was evaluated. In the overall population of
550 patients, the following parameters significantly correlated with
the median OS: predominant liver localisation of metastases yes vs
no (17.9 vs 19.5 months, respectively; P¼ 0.02), WHO performance
status 2 vs 0–1 (6.2 vs 18.5 months, respectively; Po0.0001), serum
LDH concentration abnormal vs normal (12.8 vs 21.3 months,
respectively; Po0.0001) and number of metastatic sites involved
42 vs 2 vs 1 (12.4 vs 18.0 vs 21.4 months, respectively; Po0.0001).
In the effect on median OS a significant trend was observed for the
following pathological characteristics of the primary tumour: T4 vs
T3 vs T1-2 (14.3 vs 18.9 vs 21.9 months, respectively; P¼ 0.03), N2
vs N1 vs N0 (14.4 vs 18.9 vs 20.7 months, respectively; P¼ 0.003),
mucinous carcinoma vs adenocarcinoma with mucinous compo-
nent vs adenocarcinoma (13.5 vs 13.7 vs 19.3 months, respectively;
P¼ 0.006) and differentiation grade poor vs moderate vs well (14.8
vs 20.4 vs 24.9 months, respectively; P¼ 0.0001). By univariate
analysis no effect on median OS was found for age, gender, site of
the primary tumour, prior adjuvant therapy, treatment arm,
infiltration pattern, fibroblastic reaction, lymphoid reaction, and
MSI status.
In a multivariate model all patient and primary tumour
characteristics were included. Independent predictors for median
OS in advanced CRC patients, were T stage (P¼ 0.04), differentia-
tion grade (P¼ 0.01), classification (P¼ 0.007), serum LDH at
randomisation (Po0.0001), WHO performance status (P¼ 0.01),
site of the primary tumour (P¼ 0.0008), gender (P¼ 0.03) and
metastatic sites involved (Po0.0001) (Table 3).
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Outcome in patients with metachronous vs synchronous
metastases
No significant difference in median OS was observed for patients
with metachronous vs synchronous metastases in univariate
analysis (18.5 vs 17.6 months, respectively; P¼ 0.24) (Figure 1).
In addition, to assess a possible effect of tumour burden, we
compared the largest diameter of liver metastases between the two
groups, and no difference was observed (P40.05, data not shown).
In a multivariate model, in which all patient and primary tumour
characteristics were included, the hazard ratio for metachronous vs
synchronous metastases was 1.05 (95% CI 0.81–1.36; P¼ 0.74)
(Table 3).
The median PFS in first line treatment was not significantly
different between patients with metachronous vs synchronous
metastases (7.2 vs 6.6 months, respectively; P¼ 0.23). In all, 494
patients were assessable for response in first line treatment: 235 in
the metachronous group and 259 in the synchronous group. The
overall response rate (complete plus partial tumour response) in
first line treatment was significantly better in patients with
synchronous metastases compared to patients with metachronous
metastases (38 vs 28%, respectively; P¼ 0.02). The disease control
rate (complete plus partial tumour response plus stable disease) in
first line treatment was not significantly different between patients
with synchronous and metachronous metastases (81 vs 87%,
respectively; P¼ 0.11).
Interaction of worse prognostic factors in patients with
synchronous vs metachronous metastases
Patients with synchronous vs metachronous metastases in whom
a resection of the primary tumour was performed showed
significantly different clinical and pathological characteristics.
Most of these clinicopathological features were correlated with
outcome in the total study population. However, despite the
presence of factors associated with poor prognosis, patients with
synchronous metastases had no worse survival compared to
patients with metachronous metastases.
To find a possible explanation for this observation we analysed
whether the median OS of patients with individual clinical and
Table 2 Primary tumour characteristics
Metachronous
n¼ 270
Synchronous
n¼ 280 P-value
Diameter
Median (range) 40.0
(15.0–120.0)
45.0
(15.0–140.0)
0.007a
Invasion depth
T 1–2 28 (10%) 7 (3%) 0.0006b
T 3 187 (69%) 200 (71%)
T 4 45 (17%) 59 (21%)
Unknown 10 (4%) 14 (5%)
Lymph node status
N 0 104 (39%) 50 (18%) o0.0001b
N 1 97 (36%) 97 (35%)
N 2 56 (21%) 113 (40%)
Unknown 13 (5%) 20 (7%)
Classification
Adenocarcinoma 216 (80%) 217 (78%) 0.53b
Adenocarcinoma with
mucinous component
28 (10%) 33 (12%)
Mucinous carcinoma 24 (9%) 24 (8%)
Other 2 (1%) 6 (2%)
Differentiation grade
Well 11 (4%) 11 (4%) 0.15b
Moderate 143 (53%) 125 (45%)
Poor 115 (43%) 141 (50%)
Unknown 1 (o1%) 3 (1%)
Infiltration pattern
Circumscribed 69 (26%) 48 (17%) 0.02b
Diffuse 199 (74%) 226 (81%)
Unknown 2 (o1%) 6 (2%)
Fibroblastic reaction
None/little 84 (31%) 76 (27%) 0.39b
Extensive 184 (68%) 196 (70%)
Unknown 2 (1%) 8 (3%)
Lymphoid reaction
None/little 193 (71%) 218 (78%) 0.04b
Extensive 74 (27%) 55 (20%)
Unknown 3 (1%) 7 (2%)
MSI status
pMMR 261 (97%) 271 (97%) 0.94b
dMMR 9 (3%) 9 (3%)
Abbreviations: dMMR¼ deficient mismatch repair system; pMMR¼ proficient
mismatch repair system. aWilcoxon rank sum test. bw2.
Table 1 Baseline characteristics
Metachronous
n¼ 270
Synchronous
n¼280 P-value
Age at randomisation
Median (range) 66.0 (31.0–79.0) 62.5 (34.0–81.0) o0.0001a
Gender
Male 163 (60%) 179 (64%) 0.43b
Female 107 (40%) 101 (36%)
Predominant localisation metastases
Liver 131 (49%) 240 (86%) o0.0001b
Extrahepatic 135 (50%) 39 (14%)
Unknown 4 (1%) 1 (o1%)
WHO performance status at randomisation
0 and 1 265 (98%) 262 (94%) 0.02b
2 5 (2%) 17 (6%)
Unknown 1 (o1%)
Serum LDH at randomisation
Normal 183 (68%) 161 (58%) 0.01b
4ULN 84 (31%) 117 (42%)
Unknown 3 (1%) 2 (o1%)
Site of primary tumour
Colon 114 (42%) 149 (53%) 0.002b
Rectosigmoid 65 (24%) 73 (26%)
Rectum 91 (34%) 58 (21%)
Prior adjuvant therapy
No 189 (70%) 276 (99%) o0.0001b
Yes 81 (30%) 3 (1%)
Unknown 1 (o1%)
Metastatic sites involved
1 121 (45%) 141 (50%) 0.63b
2 96 (35%) 95 (34%)
42 45 (17%) 44 (16%)
Unknown 8 (3%)
Treatment arm
Sequential 130 (48%) 138 (49%) 0.80b
Combination 140 (52%) 142 (51%)
Abbreviation: ULN¼ upper limit of normal. aWilcoxon rank sum test. bw2.
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pathological characteristics was significantly different between the
synchronous and metachronous group. However, this proved not
to be the case (P40.05 for all analyses).
Next, we compared the number of worse prognostic factors per
patient between the synchronous and metachronous group to
detect whether there was a skewed distribution. Again, this
analysis showed no significant difference in the distribution of
these characteristics per patient between the synchronous and
metachronous group (P40.05 for all analyses).
DISCUSSION
In this retrospective analysis of the phase III CAIRO trial, we
observed that CRC patients with synchronous metastases, in whom
the primary tumour was resected significantly more often, had
clinical and pathological characteristics associated with poor
prognosis compared to patients with metachronous metastases.
There is no consensus in the literature on the definition of
synchronous vs metachronous metastases. We selected a cut-off
value of 6 months after the initial diagnosis for two reasons. First,
in some patients a staging procedure is performed only after full
recovery from surgery of the primary tumour, which may take
several months in some patients. A 6-month period will assure
adequate classification of these patients. Second, metastases
developing during the first 6 months after surgery of the primary
tumour probably reflect similar tumour biology compared with
metastases detected at initial diagnosis. Therefore, we consider a
6-month cut-off value to be a clinically useful distinction between
synchronous and metachronous disease.
The unfavourable clinical characteristics that we observed more
often in patients with synchronous disease concerned a worse
performance status, an abnormal serum LDH and the colon as the
primary site of the tumour. Only the primary site of the tumour
has been previously described as being different between
synchronous and metachronous disease (Tsai et al, 2007; Ng
et al, 2009). We identified a higher T stage of the primary tumour
as an independent worse prognostic factor for median OS, which
we observed more in patients with synchronous metastases. This
confirms previously reported results of smaller series (Tsai et al,
2007; Wang et al, 2007; van der Pool et al, 2009).
Despite these poor baseline characteristics in patients with
synchronous metastases, the median OS was not decreased
compared to patients with metachronous metastases. Tsai et al
(2007) found differences in diameter, number and distribution of
liver metastases between patients with synchronous and meta-
chronous disease, and concluded that these characteristics were
of significant importance for survival. Tumour burden, as deter-
mined by the largest diameter of measurable disease and the
number of metastatic sites, were comparable between patients with
synchronous and metachronous metastases, indicating that this
parameter did not influence our results. However, several other
factors may explain this unexpected finding. First, a significant
percentage of patients with metachronous metastases were treated
with prior adjuvant chemotherapy, whereas patients with
synchronous metastases obviously were not. Theoretically, this
may have resulted in a (partial) resistance to chemotherapy in the
former group. Indeed, we observed a higher overall response rate
to first line chemotherapy in patients with synchronous meta-
stases, suggesting that this may compensate the presence of worse
prognostic factors in this group. Second, there may be hetero-
geneity between and also within the groups of patients with
synchronous and metachronous disease with regard to sympto-
matic vs asymptomatic disease and, in the latter situation, a lead
time bias caused by different time schedules for screening. Third,
survival of CRC patients could be influenced by a difference in the
presence of prognostic molecular markers between patients with
synchronous vs metachronous metastases (Pantaleo et al, 2008).
Comparing our results with the literature, only few chemo-
therapy trials performed proportional hazard models to determine
the influence of metachronous and synchronous disease on
Table 3 Prognostic value of clinical and pathological characteristics for
OS (multivariate analysis)
Multivariate
analysis for OS
Hazard ratio
(95% CI) P-value
Onset of metastasis
Metachronous 1.05 (0.81–1.36) 0.74
Synchronous R
Gender
Female 0.78 (0.63–0.97) 0.03
Male R
Site of primary tumour
Colon 1.29 (0.98–1.70) 0.0008
Rectosigmoid 0.78 (0.58–1.04)
Rectum R
WHO performance status at randomisation
0 and 1 0.53 (0.32–0.88) 0.01
2 R
Serum LDH at randomisation
4ULN 1.79 (1.44–2.23) o0.0001
Normal R
Number of metastatic sites involved
1 0.40 (0.30–0.53) o0.0001
2 0.55 (0.41–0.75)
42 R
Invasion depth
T 1–2 0.69 (0.42–1.12) 0.04
T 3 0.72 (0.55–0.93)
T4 R
Classification
Adenocarcinoma 1.00 (0.44–2.25) 0.007
Adenocarcinoma with mucinous component 1.56 (0.66–3.68)
Mucinous carcinoma 1.71 (0.71–4.13)
Other R
Differentiation grade
Well 0.69 (0.40–1.20) 0.01
Moderate 0.73 (0.59–0.91)
Poor R
Abbreviations: R¼ reference group; ULN¼ upper limit of normal.
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Figure 1 Kaplan–Meier curve for overall survival of advanced CRC
patients with metachronous (—) and synchronous (- - -) metastases in
whom a resection of the primary tumour was performed.
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median OS. Several authors showed no prognostic role for these
parameters (Kemeny et al, 1989; Saltz et al, 2000; de Gramont
et al, 2000; Tournigand et al, 2004; Colucci et al, 2005), whereas
others identified metachronous disease as a favorable prognostic
parameter (Nordic Gastrointestinal Tumor Adjuvant Therapy
Group, 1992; Graf et al, 1994; Freyer et al, 2000; Etienne-Grimaldi
et al, 2008). Our analysis differs from the published literature in
one important aspect, in that only patients with a previous
resection of the primary tumour were included in the synchronous
group. If patients with both resected and nonresected primary
tumours were included in the synchronous group, a significant
median OS benefit was observed for patients with metachronous vs
synchronous metastases (Koopman et al, 2007b). Therefore, the
conflicting results of previous studies on the prognostic role of
synchronous disease may be caused by differences among these
studies in the status of the resection of the primary tumour.
Support for our data is provided by two recent prospective
analyses in which no difference in overall survival was
observed between patients with resected synchronous vs resected
metachronous CRC liver and lung metastases, with a resection of
the primary tumour having been performed in all patients
(Ng et al, 2009; van der Pool et al, 2009).
In conclusion, despite the presence of factors associated with
poor prognosis in patients with synchronous metastases, the
parameter of synchronous and metachronous metastases was not
of prognostic value in advanced CRC patients in whom a resection
of the primary tumour was performed. Possible explanations
include a (partial) chemoresistance in patients with metachronous
disease because of prior adjuvant treatment, whereas differences
between the two groups in screening procedures resulting in a lead
time bias to diagnosis or in prognostic molecular markers remain
speculative.
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